propranolol has been researched along with Hemangioendothelioma in 21 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Hemangioendothelioma: A neoplasm derived from blood vessels, characterized by numerous prominent endothelial cells that occur singly, in aggregates, and as the lining of congeries of vascular tubes or channels. Hemangioendotheliomas are relatively rare and are of intermediate malignancy (between benign hemangiomas and conventional angiosarcomas). They affect men and women about equally and rarely develop in childhood. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1866)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Transcatheter arterial embolization combined with propranolol is an effective treatment for life-threatening infantile hepatic hemangioendothelioma." | 7.96 | Infantile hepatic hemangioendothelioma associated with pulmonary artery hypertension and cardiac insufficiency successfully treated with transcatheter arterial embolization and propranolol: A case report. ( Guo, L; Li, J; Song, D; Wang, L; Wu, C; Yin, J, 2020) |
| "A newborn with unresectable kaposiform hemangioendothelioma associated with Kasabach Merritt phenomenon, unresponsive to vincristine and prednisone, received second-line treatment with propranolol at a dose of 2 mg/kg/day, starting at 2 months of life and continued for 13 months." | 7.83 | Successful Propranolol Treatment of a Kaposiform Hemangioendothelioma Apparently Resistant to Propranolol. ( Berti, E; Calvani, M; Defilippi, C; Della Bona, ML; Donzelli, G; Favre, C; Filippi, L; la Marca, G; Perrone, A; Tamburini, A, 2016) |
| "There is currently no consensus on the second-line management of Kaposiform hemangioendothelioma (KHE) that was resistant to prednisolone and vincristine." | 7.81 | Successful treatment of Kaposiform hemangioendothelioma with everolimus. ( Ito, S; Miyazaki, O; Mori, T; Nakazawa, A; Terashima, K; Uno, T, 2015) |
| "Propranolol is a non-selective beta-adrenergic antagonist successfully used in a case of kaposiform hemangioendothelioma (KHE) associated with Kasabach-Merritt phenomenon (KMP)." | 7.78 | Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon. ( Blei, F; Carcao, M; Chiu, YE; Drolet, BA; Fangusaro, J; Kelly, ME; Krol, A; Lofgren, S; Mancini, AJ; Metry, DW; Pope, E; Recht, M; Silverman, RA; Tom, WL, 2012) |
| "A brief comment on efficacy and safety of propranolol in the treatment of parotid hemangioma is presented, with illustration of a typical case." | 7.77 | Comment on efficacy and safety of propranolol in the treatment of parotid hemangioma. ( Zheng, JW, 2011) |
| "Kaposiform hemangioendothelioma is a rare vascular tumor in children." | 5.37 | Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: a new indication for propranolol treatment. ( de Blaauw, I; Hermans, DJ; Kool, LJ; van Beynum, IM; van der Vijver, RJ; van der Vleuten, CJ, 2011) |
| "Consumptive hypothyroidism due to cutaneous hemangioma and hepatic hemangioendothelioma can be managed with propranolol and low-dose sirolimus." | 4.12 | Severe consumptive hypothyroidism in hepatic hemangioendothelioma. ( Dubinski, I; Häberle, B; Küppers, J; Lurz, E; Schmid, I; Schmidt, H; Walther, A, 2022) |
| "Transcatheter arterial embolization combined with propranolol is an effective treatment for life-threatening infantile hepatic hemangioendothelioma." | 3.96 | Infantile hepatic hemangioendothelioma associated with pulmonary artery hypertension and cardiac insufficiency successfully treated with transcatheter arterial embolization and propranolol: A case report. ( Guo, L; Li, J; Song, D; Wang, L; Wu, C; Yin, J, 2020) |
| "Sirolimus is an effective therapy for children with kaposiform hemangioendothelioma with or without the Kasabach-Merritt phenomenon." | 3.88 | ( Dillingham, CS; Givner, LB; McLean, TW; Rinker, EK; Russell, TB, 2018) |
| "A newborn with unresectable kaposiform hemangioendothelioma associated with Kasabach Merritt phenomenon, unresponsive to vincristine and prednisone, received second-line treatment with propranolol at a dose of 2 mg/kg/day, starting at 2 months of life and continued for 13 months." | 3.83 | Successful Propranolol Treatment of a Kaposiform Hemangioendothelioma Apparently Resistant to Propranolol. ( Berti, E; Calvani, M; Defilippi, C; Della Bona, ML; Donzelli, G; Favre, C; Filippi, L; la Marca, G; Perrone, A; Tamburini, A, 2016) |
| "There is currently no consensus on the second-line management of Kaposiform hemangioendothelioma (KHE) that was resistant to prednisolone and vincristine." | 3.81 | Successful treatment of Kaposiform hemangioendothelioma with everolimus. ( Ito, S; Miyazaki, O; Mori, T; Nakazawa, A; Terashima, K; Uno, T, 2015) |
| "Propranolol is a non-selective beta-adrenergic antagonist successfully used in a case of kaposiform hemangioendothelioma (KHE) associated with Kasabach-Merritt phenomenon (KMP)." | 3.78 | Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon. ( Blei, F; Carcao, M; Chiu, YE; Drolet, BA; Fangusaro, J; Kelly, ME; Krol, A; Lofgren, S; Mancini, AJ; Metry, DW; Pope, E; Recht, M; Silverman, RA; Tom, WL, 2012) |
| "A brief comment on efficacy and safety of propranolol in the treatment of parotid hemangioma is presented, with illustration of a typical case." | 3.77 | Comment on efficacy and safety of propranolol in the treatment of parotid hemangioma. ( Zheng, JW, 2011) |
| "The patient has hypoxemia due to abdominal distention during the follow-up period." | 1.46 | Beta blocker and steroid therapy in the treatment of infantile hepatic hemangioendothelioma. ( Bör, Ö; Düzenli Kar, Y; Kebapçı, M; Özdemir, ZC; Şöhret, NC, 2017) |
| "Kaposiform hemangioendothelioma is a rare vascular tumor in children." | 1.37 | Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: a new indication for propranolol treatment. ( de Blaauw, I; Hermans, DJ; Kool, LJ; van Beynum, IM; van der Vijver, RJ; van der Vleuten, CJ, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 17 (80.95) | 24.3611 |
| 2020's | 4 (19.05) | 2.80 |
| Authors | Studies |
|---|---|
| Walther, A | 1 |
| Häberle, B | 1 |
| Küppers, J | 1 |
| Lurz, E | 1 |
| Schmid, I | 1 |
| Schmidt, H | 1 |
| Dubinski, I | 1 |
| Yu, L | 2 |
| Wei, L | 2 |
| Ma, L | 2 |
| Li, L | 2 |
| Wang, L | 1 |
| Song, D | 1 |
| Wu, C | 1 |
| Li, J | 1 |
| Yin, J | 1 |
| Guo, L | 1 |
| Maaloul, I | 1 |
| Aloulou, H | 1 |
| Hentati, Y | 1 |
| Kamoun, T | 1 |
| Mnif, Z | 1 |
| Hachicha, M | 1 |
| Özdemir, ZC | 1 |
| Düzenli Kar, Y | 1 |
| Şöhret, NC | 1 |
| Kebapçı, M | 1 |
| Bör, Ö | 1 |
| Russell, TB | 1 |
| Rinker, EK | 1 |
| Dillingham, CS | 1 |
| Givner, LB | 1 |
| McLean, TW | 1 |
| Emad, A | 1 |
| Fadel, S | 1 |
| El Wakeel, M | 1 |
| Nagy, N | 1 |
| Zamzam, M | 1 |
| Kieran, MW | 1 |
| El Haddad, A | 1 |
| Stiles, JM | 1 |
| Amaya, C | 1 |
| Rains, S | 1 |
| Diaz, D | 1 |
| Pham, R | 1 |
| Battiste, J | 1 |
| Modiano, JF | 1 |
| Kokta, V | 1 |
| Boucheron, LE | 1 |
| Mitchell, DC | 1 |
| Bryan, BA | 1 |
| Tlougan, BE | 1 |
| Lee, MT | 1 |
| Drolet, BA | 2 |
| Frieden, IJ | 1 |
| Adams, DM | 1 |
| Garzon, MC | 1 |
| Wang, Z | 1 |
| Li, K | 1 |
| Dong, K | 1 |
| Xiao, X | 1 |
| Zheng, S | 1 |
| Uno, T | 1 |
| Ito, S | 1 |
| Nakazawa, A | 1 |
| Miyazaki, O | 1 |
| Mori, T | 1 |
| Terashima, K | 1 |
| Korsaga-Somé, N | 1 |
| Maruani, A | 1 |
| Abdo, I | 1 |
| Favrais, G | 1 |
| Lorette, G | 1 |
| Filippi, L | 1 |
| Tamburini, A | 1 |
| Berti, E | 1 |
| Perrone, A | 1 |
| Defilippi, C | 1 |
| Favre, C | 1 |
| Calvani, M | 1 |
| Della Bona, ML | 1 |
| la Marca, G | 1 |
| Donzelli, G | 1 |
| Sarialioglu, F | 1 |
| Erbay, A | 1 |
| Demir, S | 1 |
| Morais, P | 1 |
| Magina, S | 1 |
| Mateus, M | 1 |
| Trindade, E | 1 |
| Jesus, JM | 1 |
| Azevedo, F | 1 |
| Hermans, DJ | 1 |
| van Beynum, IM | 1 |
| van der Vijver, RJ | 1 |
| Kool, LJ | 1 |
| de Blaauw, I | 1 |
| van der Vleuten, CJ | 1 |
| Zheng, JW | 1 |
| Avagyan, S | 1 |
| Klein, M | 1 |
| Kerkar, N | 1 |
| Demattia, A | 1 |
| Blei, F | 3 |
| Lee, S | 1 |
| Rosenberg, HK | 1 |
| Arnon, R | 1 |
| Chiu, YE | 1 |
| Carcao, M | 1 |
| Fangusaro, J | 1 |
| Kelly, ME | 1 |
| Krol, A | 1 |
| Lofgren, S | 1 |
| Mancini, AJ | 1 |
| Metry, DW | 1 |
| Recht, M | 1 |
| Silverman, RA | 1 |
| Tom, WL | 1 |
| Pope, E | 1 |
| Hochman, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sirolimus in the Treatment for Propranolol-resistant Infantile Hepatic Hemangioendothelioma[NCT04406870] | Phase 4 | 36 participants (Anticipated) | Interventional | 2020-07-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for propranolol and Hemangioendothelioma
| Article | Year |
|---|---|
Medical management of vascular anomalies.
Topics: Adrenergic beta-Antagonists; Hemangioendothelioma; Hemangioma; Humans; Kasabach-Merritt Syndrome; Pr | 2012 |
Management of vascular tumors.
Topics: Adrenergic beta-Antagonists; Child; Granuloma, Pyogenic; Hemangioendothelioma; Hemangioma; Humans; K | 2012 |
19 other studies available for propranolol and Hemangioendothelioma
| Article | Year |
|---|---|
Severe consumptive hypothyroidism in hepatic hemangioendothelioma.
Topics: Hemangioendothelioma; Humans; Hypothyroidism; Infant; Liver Neoplasms; Male; Propranolol; Sirolimus; | 2022 |
First report of oral atenolol for treatment of kaposiform hemangioendothelioma, a viable alternative to propranolol.
Topics: Atenolol; Hemangioendothelioma; Humans; Kasabach-Merritt Syndrome; Propranolol; Sarcoma, Kaposi | 2023 |
First report of oral atenolol for treatment of kaposiform hemangioendothelioma, a viable alternative to propranolol.
Topics: Atenolol; Hemangioendothelioma; Humans; Kasabach-Merritt Syndrome; Propranolol; Sarcoma, Kaposi | 2023 |
First report of oral atenolol for treatment of kaposiform hemangioendothelioma, a viable alternative to propranolol.
Topics: Atenolol; Hemangioendothelioma; Humans; Kasabach-Merritt Syndrome; Propranolol; Sarcoma, Kaposi | 2023 |
First report of oral atenolol for treatment of kaposiform hemangioendothelioma, a viable alternative to propranolol.
Topics: Atenolol; Hemangioendothelioma; Humans; Kasabach-Merritt Syndrome; Propranolol; Sarcoma, Kaposi | 2023 |
Infantile hepatic hemangioendothelioma associated with pulmonary artery hypertension and cardiac insufficiency successfully treated with transcatheter arterial embolization and propranolol: A case report.
Topics: Antihypertensive Agents; Catheterization; Combined Modality Therapy; Embolization, Therapeutic; Hear | 2020 |
Infantile hepatic hemangioendothelioma successfully treated by low dose of propranolol.
Topics: Dose-Response Relationship, Drug; Female; Hemangioendothelioma; Humans; Infant; Liver Neoplasms; Pro | 2017 |
Beta blocker and steroid therapy in the treatment of infantile hepatic hemangioendothelioma.
Topics: Adrenergic beta-Antagonists; Glucocorticoids; Hemangioendothelioma; Hepatomegaly; Humans; Hypothyroi | 2017 |
Topics: Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Drug Therapy, | 2018 |
Outcome of Children Treated for Infantile Hepatic Hemangioendothelioma.
Topics: Antineoplastic Agents, Hormonal; Combined Modality Therapy; Female; Follow-Up Studies; Hemangioendot | 2020 |
Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma.
Topics: Adrenergic beta-Antagonists; Animals; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Movement | 2013 |
Medical management of tumors associated with Kasabach-Merritt phenomenon: an expert survey.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Data Collection; Hemangioendothelioma; Hemangioma; H | 2013 |
Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon.
Topics: Adrenergic beta-Antagonists; Female; Hemangioendothelioma; Hemangioma; Humans; Kasabach-Merritt Synd | 2014 |
Successful treatment of Kaposiform hemangioendothelioma with everolimus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Drug Resistance, Neoplasm; Everolimus; Hemang | 2015 |
[Kasabach-Merritt phenomenon (KMP) exacerbated by platelet transfusions].
Topics: Aspirin; Axilla; Combined Modality Therapy; Compression Bandages; Disease Progression; Disseminated | 2015 |
Successful Propranolol Treatment of a Kaposiform Hemangioendothelioma Apparently Resistant to Propranolol.
Topics: Drug Resistance, Neoplasm; Hemangioendothelioma; Humans; Infant, Newborn; Infant, Newborn, Diseases; | 2016 |
Response of infantile hepatic hemangioma to propranolol resistant to high-dose methylprednisolone and interferon-α therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Hemangioendothelioma; Hum | 2010 |
Efficacy and safety of propranolol in the treatment of parotid hemangioma.
Topics: Adrenergic beta-Antagonists; Female; Hemangioendothelioma; Hemangioma; Humans; Infant; Liver Neoplas | 2011 |
Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: a new indication for propranolol treatment.
Topics: Adrenergic beta-Antagonists; Antineoplastic Agents, Phytogenic; Disseminated Intravascular Coagulati | 2011 |
Comment on efficacy and safety of propranolol in the treatment of parotid hemangioma.
Topics: Adrenergic beta-Antagonists; Female; Hemangioendothelioma; Hemangioma; Humans; Liver Neoplasms; Neop | 2011 |
Propranolol as a first-line treatment for diffuse infantile hepatic hemangioendothelioma.
Topics: Adrenergic beta-2 Receptor Antagonists; Antineoplastic Agents; Congenital Hypothyroidism; Drug Monit | 2013 |
Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon.
Topics: Adrenergic beta-Antagonists; Child, Preschool; Female; Hemangioendothelioma; Hemangioma; Humans; Inf | 2012 |